US FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis
Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents
Johnson & Johnson Vision to launch ELITA Platform during ESCRS 2023
The new platform incorporates the SILK procedure, allowing surgeons to perform refractive correction on patients with myopia.
Corneal cross-linking effective for keratoconus relapse after penetrating keratoplasty
A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.
Bausch + Lomb announces acquisition of Xiidra from Novartis
The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.
FDA issues CRL for aflibercept 8 mg from Regeneron Pharmaceuticals
The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Dr Justis P. Ehlers dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Dr Dilsher Dhoot discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
Clinical trial offers insight into development of KSI-301
While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.
Hypersonic vitrectomy a novel technology for removing vitreous
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Dr Sunir J. Garg explains how retinal surgeons can remove the vitreous gel with more efficiency.
Significance of the YOSEMITE and RHINE 2-year DMO clinical trial results
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
Approaches for managing treatment of patients with endophthalmitis
Via four cases, Dr Harry Flynn describes a variety of endophthalmitis management options for retinal surgeons.
Treat-to-maintain drug vorolanib ushers in new era for retinal therapy
EyePoint Pharmaceuticals hopes to usher in a new paradigm of retinal eye disease treatments with their candidate EYP-190.
ARMOR study: Evaluating antibiotic resistance in the treatment of staph infections
Dr Penny Asbell discusses her presentation entitled, “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."
Searching for uveitis: How to ensure you don’t miss a diagnosis
Dr Yasha S. Modi discusses his best tips and tricks for finding and diagnosing infectious uveitis.
Phase 1 trial finds at-home subcutaneous injection option safe, effective for the treatment of wet AMD, DMO
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous anti-VEGF injection option in development for the treatment of wet AMD and DMO.
OC-01 (varenicline solution) investigated as possible treatment for dry eye symptoms, signs
Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.
Cell therapy shows promise for patients with dry AMD, geographic atrophy
The OpRegen trial is a cell therapy trial, looking to explore potential safety and efficacy for patients with advanced dry age-related macular degeneration (AMD).
Binocular vision affected by amblyopia, research suggests
The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.
POAG study hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma
Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.
Ill-timed corneal crosslinking led to permanent changes in corneal structure in patients with keratoconus
The study evaluates three separate cases, each of which experienced irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the COVID-19 pandemic.
Data reveals efficacy of bispecific targeting of VEGF, Ang2 pathways
Prof. Anat Loewenstein discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular oedema.
Investigating efficacy of OC-02 to stimulate the trigeminal nerve for the treatment of dry eyes
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
Advancing IOL technology for treatment of presbyopia
Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
Positive topline data from Saturn-2 Phase 3 trial encourages Tarsus to file NDA in 2022
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
First MINIject surgery completed in the UK
iStar Medical announced the expansion of its commercial rollout of its MIGS implant MINIject® to the UK.
'Focus on Child Eye Health' initiative introduced by IAPB
The International Agency for the Prevention of Blindness (IAPB) recently announced an expansion of their ‘Focus on Glaucoma’ and ‘Focus on Diabetes’ series with their new ‘Focus on Child Eye Health’ series in partnership with CooperVision.
2 Clarke Drive Cranbury, NJ 08512